| Identification | Back Directory | [Name]
Prolactin-Releasing Peptide (1-31) (human) | [CAS]
215510-22-8 | [Synonyms]
Human PrRP-31
PrRP31 (huMan), Preprolactin (23-53) (huMan)
H-Ser-Arg-Thr-His-Arg-His-Ser-Met-Glu-Ile-Arg-Thr-Pro-Asp-Ile-Asn-Pro-Ala-Trp-Tyr-Ala-Ser-Arg-Gly-Ile-Arg-Pro-Val-Gly-Arg-Phe-NH2 | [Molecular Formula]
C160H252N56O42S | [MOL File]
215510-22-8.mol | [Molecular Weight]
3664.13 |
| Chemical Properties | Back Directory | [solubility ]
Water: 1 mg/ml | [form ]
A lyophilized powder | [color ]
White to off-white | [Sequence]
Ser-Arg-Thr-His-Arg-His-Ser-Met-Glu-Ile-Arg-Thr-Pro-Asp-Ile-Asn-Pro-Ala-Trp-Tyr-Ala-Ser-Arg-Gly-Ile-Arg-Pro-Val-Gly-Arg-Phe-NH2 |
| Hazard Information | Back Directory | [Uses]
Prolactin Releasing Peptide (1-31), human is a high affinity GPR10 ligand that cause the release of the prolactin. Prolactin Releasing Peptide (1-31) binds to GPR10 for human and rats with Ki values of 1.03 nM and 0.33 nM, respectively. Prolactin Releasing Peptide (1-31) can be used for the research of the hypothalamo-pituitary axis[1][2]. | [in vivo]
Prolactin Releasing Peptide (1-31) (human) (ICV, 5 nM) increases plasma FSH, total plasma testosterone and significantly increased the release of LHRH from hypothalamic explants in vitro[2].
Prolactin Releasing Peptide (1-31) (human) (ICV, 100 nM) increases the hypothalanic peptides involved in the control of pituitary hormone release, vasoactive intestinal peptide (VIP) and galanin but had no effect on orexin A secretion[2]. | [References]
[1] Langmead CJ, et al. Characterization of the binding of [(125)I]-human prolactin releasing peptide (PrRP) to GPR10, a novel G protein coupled receptor. Characterization of the binding of [(125)I]-human prolactin releasing peptide (PrRP) to GPR10, a novel G protein coupled receptor. DOI:10.1038/sj.bjp.0703617
[2] L J Seal, et al. Prolactin releasing peptide (PrRP) stimulates luteinizing hormone (LH) and follicle stimulating hormone (FSH) via a hypothalamic mechanism in male rats. Endocrinology. 2000 May;141(5):1909-12. DOI:10.1210/endo.141.5.7528 |
|
|